Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Fiber gummies: a tasty new weapon against obesity?

NCT ID NCT07758387

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This trial tests whether gummies containing polydextrose, a type of dietary fiber, can help adults with overweight or obesity lose weight. Participants will take the gummies before meals for 24 weeks, alongside standard diet and exercise advice. The study compares weight loss, appetite, and safety against a placebo to see if this simple supplement could support weight management.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Polydextrose gummies (a dietary fiber supplement)
What this could lead to
If effective, polydextrose gummies could offer a simple, non-drug aid for weight management in people with overweight or obesity.
What could go wrong
This is a small, early-stage trial, and the effect on weight loss may be modest. Gastrointestinal discomfort is possible, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 96 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 70 years. * Body mass index (BMI) between 25 and 39.9 kg/m² (overweight or obesity class I-II). * Stable body weight (no change greater than 3%) in the 3 months before joining the study. * Usually eat at least 2 meals per day. * Able and willing to follow the study procedures for 24 weeks, attend all scheduled visits, and complete the required records. * Willing and able to sign the informed consent form. Exclusion Criteria: * Type 2 diabetes with glycated hemoglobin (HbA1c) greater than 7%, type 1 diabetes, or type 2 diabetes treated with multiple daily insulin injections. * Treatment with sodium-glucose co-transporter-2 (SGLT2) inhibitors for diabetes, heart failure, or chronic kidney disease. * Uncontrolled thyroid disease \[thyroid-stimulating hormone (TSH) outside the normal range\] or recent changes in thyroid medication in the last 3 months. * Significant gastrointestinal disease (such as severe irritable bowel syndrome, Crohn's disease, or ulcerative colitis). * History of bariatric surgery. * Liver cirrhosis. * Advanced chronic kidney disease (stage IV-V). * Following a very low-calorie diet (less than 800 kcal/day). * Alcohol dependence or heavy alcohol use that, in the investigator's opinion, could affect the study. * Current or recent eating disorder. * Planning to start or recently started a specific weight-loss diet different from the one recommended by the study endocrinology service. * Currently taking or having taken in the last 3 months medicines that affect appetite or body weight (such as anorectic drugs, GLP-1 receptor agonists, chronic corticosteroids, antipsychotics, or fiber supplements). * Pregnancy or breastfeeding. * Women of childbearing potential who are trying to become pregnant or plan to become pregnant during the study. * Known allergy or intolerance to any ingredient of the study gummies. * History of severe gastrointestinal problems with fermentable fibers.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity & overweight are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Universitario Príncipe de Asturias

    Alcalá de Henares, Madrid, 28805, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.